ARLINGTON, Va. — HDA president and CEO Chester “Chip” Davis, Jr., released the following statement in response to recent commentary related to the COVID-19 vaccination effort: “HDA and the health care distribution industry are committed to doing whatever is necessary to assist the Biden administration in meeting its goal of administering 100 million vaccines to
ARLINGTON, Va. — HDA president and CEO Chester “Chip” Davis, Jr., released a statement commenting on passage of the COVID-19 emergency relief package by the U.S. House of Representatives and the U.S. Senate. “HDA applauds Congress for passing the bipartisan economic stimulus package that will provide much needed relief to the businesses and millions of
ARLINGTON, Va. — HDA president and CEO Chester “Chip” Davis, Jr., released the following statement on the U.S. Food and Drug Administration’s (FDA) decision to grant Emergency Use Authorization of the first COVID-19 vaccine, manufactured by Pfizer and BioNTech: “Today’s decision by the FDA marks a historic turning point in the fight against this global
ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) released policy principles reaffirming the pharmaceutical distribution industry’s commitment to assisting the country and frontline healthcare providers during pandemics and public health emergencies. HDA highlights four priority areas: Supply Chain Coordination: Coordination between the public and private sector is key to addressing public health crises. Accordingly, a consolidated contact within the
ARLINGTON, Va. — Taking on a new leadership role is never easy; taking the helm during a global pandemic, however, especially when job No. 1 for the organization’s members involves keeping the country’s vital medical supply chain running smoothly, defines daunting. But being named president and chief executive officer of the Healthcare Distribution Alliance
ARLINGTON, Va. — HDA has released a two-minute video that further reinforces the pharmaceutical distribution industry’s critical function as it adapts and rises to the challenge of COVID-19, while also continuing the vital work of delivering the medicines Americans rely on to manage their daily health care needs. The video features HDA president and CEO
ARLINGTON, Va.— On April 27, HDA president and CEO Chester “Chip” Davis, sent a letter to the leadership of major pharmacy organizations to underscore how individual distributors typically manage, and are adapting to, the unprecedented supply challenges presented by COVID-19. Recipients included: American Association of Colleges of Pharmacy; American Pharmacists Association; American Society of Health-System Pharmacists;
Across the country, brave, frontline health care professionals are working around the clock as our nation grapples with the COVID-19 pandemic. These workers — the true heroes of the pandemic — are treating patients, maintaining vital health care operations and serving as emergency responders. In this time of crisis, it is also important to remember
ARLINGTON, Va. – In response to the Food and Drug Administration’s (FDA) proposed rule on prescription drug importation, Healthcare Distribution Alliance (HDA) president and CEO Chester “Chip” Davis, Jr. released the following statement: “As the vital link within the healthcare ecosystem, HDA’s pharmaceutical distributor members share FDA’s commitment to ensuring that Americans have access to
ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) board of directors’ executive committee announced Monday the appointment of Chester “Chip” Davis, to the position of president and chief executive officer. Davis will join HDA during March of this year. He joins HDA coming from the Association for Accessible Medicines (AAM), the nation’s leading trade association
The public continues to name health care costs — and prescription drugs in particular — as a top priority. A recent survey from the Kaiser Family Foundation found that eight in 10 Americans say the cost of prescription drugs is unreasonable. At the same time, the value of generic medicines is well established. Consider this:
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. This past June, Secretary of Health and Human Services Alex Azar told the Senate Finance Committee, “We need a strong, robust generic market.” He followed this statement with an observation that resonated for many of the member companies of the
WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics
The Association for Accessible Medicines (AAM) said a new report shows that abuse of the Food and Drug Administration’s Risk Evaluation Mitigation Strategies (REMS) safety program is hampering the market entry of new generic drugs. This week, AAM said a report by Alex Brill, CEO of economic policy consultancy Matrix Global Advisors, titled “REMS and